Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches

 
• By Anju Ghangurde

A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.

Corner
LUPIN'S US GENERICS BUSINESS HAS TURNED THE CORNER • Source: Shutterstock

More from Business

More from Scrip